Company updateCNBC-TV18
Biocon gets European Commission's market authorisation for biosimilar for breast cancer treatment
Positive+20
GreyOak summary
Biocon Ltd. received European Commission market authorization for Pebrilzo, its biosimilar pertuzumab, to treat HER2-positive breast cancer. This marks the company's fifth oncology biosimilar approval globally. The news follows a recent quarterly report showing a 57.4% decline in net profit to ₹56.7 crore.
What it affects
- BioconBIOCONPositive +20
Rolling sentiment Positive +18
Source
Read the original at CNBC-TV18More Biocon news
- Biocon's Pebrilzo gets first EMA tailored pathway approvalBusinessLine · Company update ·
- Biocon gets EU nod for Pebrilzo breast cancer drugBusiness Standard · Company update ·